TNON Stock — Tenon Medical Inc

Tenon Medical Inc (TNON)

Updated October 16, 2026.

TNON is a Stock. Total return is -100.0% over the past 4.4 years, 206.6 points behind SPY at 106.6%.

Tenon Medical is a medical device company that develops implant systems for treating severe lower back pain caused by sacroiliac joint disorders. The company's primary offering is the Catamaran SI-Joint Fusion System, which uses a titanium implant to stabilize and fuse the sacroiliac joint through a minimally invasive approach. The company does not currently distribute dividends.

TNON performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 4.4 years, 206.6 points behind SPY at 106.6%. Over the past year its total return — price change plus distributions reinvested — is -93.8%. Its deepest 1-year drawdown was 94.6%.

TNON key facts

Asset type

Stock

Asset class

Equity

Inception date

05/12/2022

Distribution frequency

None

Last close

$2.70 (as of 2026-10-16)

Market cap

$7,259,584

Average volume

210693.0

Beta

1.356

Payout ratio

0.0%

EPS

$-44.86

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TNON risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 94.6%.

Who may consider TNON — and who may not

It is a weaker fit for investors who need monthly cash flow (TNON does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TNON

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions